United Therapeutics is rated a Buy due to strong core business growth and a promising late-stage drug pipeline. Management aims to reach a $1 billion quarterly revenue run rate by the end of 2027 from currently approved products, establishing a solid commercial foundation. Key upcoming catalysts include Ralinepag and Nebulized Tyvaso for idiopathic pulmonary fibrosis, which could generate multi-billion dollar peak sales if approved. Risks involve FDA approval uncertainty, margin pressure, US sales concentration, and insider selling, but the company’s consistent cash flow and profitability reduce major concerns.
STARLUX Airlines has introduced the AIRSORAYAMA Silver, the world's largest flying canvas, featuring a unique liquid-metal livery designed by Japanese artist Hajime Sorayama. The aircraft, an Airbus A350-1000, was unveiled in Toulouse and will be pil...
Intertape Polymer Corp (IPG) has introduced a new PCR Air Pillow Film made with 50% recycled materials, including 35% post-consumer recycled content. This high-performance packaging film is designed to help companies meet sustainability goals without...
Marathon's Bitcoin mining hash rate has increased to 31.5 exahashes per second (EH/s), reflecting intensified competition among miners. This growth indicates Marathon's expanding mining capacity and efforts to secure a larger share of Bitcoin rewards...
Spring Valley Acquisition Corp. III shareholders have approved a business combination with General Fusion, a leader in fusion energy technology. The merger will create the first publicly traded pure-play fusion company, expected to trade on Nasdaq un...
Ademi LLP is investigating Crinetics' recent $10 billion sale to Vertex for potential breaches of fiduciary duty by Crinetics' board and unfair deal terms. The deal offers Crinetics shareholders $85 per share but includes penalties that limit competi...
